influx via Ca v 3.2 activates the calcineurin/nuclear factor of the activated T-cell (NFAT) signaling pathway, and a previously unidentified NFAT binding site is identified within the mouse Sox9 promoter using a luciferase reporter assay and gel shift and ChIP studies. Our findings define a previously unidentified mechanism that Ca 2+ influx via the Ca v 3.2 T-type Ca 2+ channel regulates Sox9 expression through the calcineurin/NFAT signaling pathway during tracheal chondrogenesis. C ongenital tracheal malformations (CTMs), such as tracheal stenosis, are rare human conditions caused by defective development of the cartilaginous trachea (1, 2) . Made of a series of imperfect rings interconnected by fibrous tissue, the trachea is flexible enough to bend yet rigid enough to remain widely patent during respiration. Each ring, with the exception of the cricoid cartilage (a true ring), is actually an arch that rests on the posterior membranous trachea, which separates the airway and esophagus. As might be expected from their functional importance, defects in the tracheal rings can compromise the airway lumen and lead to tracheal stenosis, a life-threatening condition (2, 3) . The pathogenesis of the tracheal stenosis has not been elucidated.
The development of mouse trachea begins as a simple outpouching from ventral foregut endoderm at about embryonic day (E) 9.5 (4). The foregut is then further partitioned into the ventral trachea and the dorsal esophagus at E11.5 along the dorsoventral axis (5) . Cartilage rings and smooth muscle of the trachea tube are differentiated from the trachea surrounding the splanchnic mesenchyme at E13.5-E15.5 (6, 7) . Cartilage rings are formed by proliferation and then condensation of chondrogenic-committed mesenchymal cells. These condensed mesenchymal cells then differentiate into chondrocytes that express cartilage-specific proteins, such as type II collagen (Col2a1) (8) .
The transcription factor sex determination region of Y chromosome (SRY)-related high-mobility group-Box gene 9 (Sox9) is involved in chondrogenesis, as well as sex determination, during embryonic development (9) (10) (11) . Sox9 plays critical roles in each step of chondrogenesis and is expressed in chondrogenic progenitors and differentiated chondrocytes but not in hypertrophic chondrocytes (12) (13) (14) . Mutation of the human SOX9 gene causes a severe skeletal malformation syndrome called campomelic dysplasia (15) . In mice, loss of one allele of Sox9 gene (Sox9
) is perinatallethal because of severe bone malformation and respiratory deficiency. Sox9
+/− mice also show abnormal cartilage formation, including tracheal cartilage (16) . Interestingly, transgenic mice with overexpression of Sox9 driven by the Col2a1 promoter showed chondrodysplasia due to inhibited chondrocyte proliferation (17) . These studies demonstrate that Sox9 expression is crucial for normal development of cartilage and needs to be precisely regulated.
Voltage-gated Ca 2+ channels (VGCCs) are key regulators of Ca 2+ influx in many cell types, including chondrocytes and osteoblasts (18, 19) , and Ca 2+ influx is involved in the differentiation of chondrogenic mesenchymal cells into chondrocytes (20) . Ca v 3.2 T-type and Ca v 1.2 L-type Ca 2+ channels, but not other VGCCs, are regulated by 1,25-dihydroxyvitamin D3 in murine osteoblast cells (21) , and these two channels are dynamically regulated in cartilage and bone during endochondral development (18) . However, the roles of VGCCs, especially T-type Ca 2+ channels, in tracheal chondrogenesis remain unclear. T-type Ca 2+ channels (Ca v 3 family) are involved in diverse physiological processes, such as hormone secretion, gene expression, cell proliferation and differentiation, and development of neuronal and cardiac diseases (22, 23) . Three T-type Ca 2+ channel subunits have been identified: Ca v 3.1, Ca v 3.2, and Ca v 3.3 (24) .
Significance
The tracheal cartilage rings are important for protecting and maintaining the airway. However, the chondrogenesis of tracheal cartilage is not completely understood. We demonstrate that the Ca v 3.2 T-type calcium channel is required for normal tracheal cartilage ring formation. Calcium influx via Ca v 3.2 induces chondrogenesis and up-regulates a chondrogenic master gene, sex determination region of Y chromosome (SRY)-related high-mobility group-Box gene 9 (Sox9), via a calcium and calcineurin-dependent pathway. Ca v 3.2-dependent regulation of Sox9 is mediated by a newly identified nuclear factor of activated T-cell binding site on the Sox9 promoter. Our study provides novel insight into the roles of Ca v 3.2 T-type calcium channels in tracheal development. Moreover, CACNA1H, the human homolog of the mouse Ca v 3.2-encoding gene, may be a potential candidate gene involved in congenital tracheal stenosis in humans.
Polymorphism or mutations of the human Ca v 3.2 gene are associated with childhood-absent epilepsy, idiopathic generalized epilepsy, and autism-spectrum disorders (25) (26) (27) −/− mice were narrow and elliptically shaped, with the long axis oriented in the anterior-posterior direction (Fig. S1A) . Alcian blue staining showed that WT mice had continuous, distinct cartilaginous rings that resembled arches, whereas the cartilaginous rings of the Ca v 3.2 −/− mice were frequently disrupted anteriorly, resembling an arch missing its keystone, thus collapsing the transverse diameter of the tracheal airway (Fig. 1A) . The mean number of disrupted cartilaginous rings in adult Ca v 3.2 −/− mice was 9.95 ± 0.51 (n = 25) vs. none in WT mice (n = 20). We also examined the cartilage ring pattern in the bronchi and found there is no difference between the WT and Ca v 3.2 −/− mice (Fig. S1B ). To determine whether the cartilage disruption was congenital, we examined tracheas from embryos and neonatal pups and found abnormal tracheal rings at both E14.5 and postnatal day 1, with no ring abnormalities in age-matched WT embryos and neonates (Fig. 1A) . Almost all of the cartilage rings were disrupted in the Ca v 3.2 −/− trachea at E14.5 and postnatal day 1. We also examined cricoid cartilage and cartilages from the xiphistemum, ear, nose, and articular cartilage and found no morphological difference between WT and Ca v 3.2 −/− mice (Fig. S1C) (Fig. 1B) . These observations were supported by RT-PCR analysis of Ca v 3.2 transcripts in isolated cartilaginous rings and epithelia from neonatal and adult tracheas (Fig. 1C) . In addition, RT-PCR revealed clear, tissuespecific expression of aggrecan (Agc1, a marker of chondrogenic cells) and secretoglobin 1a1 [Scgb1a1, an epithelium marker (35) ] in tracheal cartilage and the epithelium, respectively, which indicates no cross-contamination of tissues (Fig. 1C) Fig. 2A) . Ca v 3.2 overexpression significantly increased the mRNA levels of chondrogenic marker genes Sox9, Agc1, and Col2a1 in ATDC5 cells, which could be inhibited by the addition of NNC 55-0396 (Fig. 2B) . The reduced percentages of Sox9, Agc1, and Col2a1 by NNC 55-0396 in Ca v 3.2-transfected ATDC5 cells are similar (68 ± 3.6%, 63 ± 3.2%, and 65 ± 2.6%, respectively). To test whether the above-described effects in an established cell line are conserved in embryonic cells, we established high-density micromass cell cultures of embryonic limb bud mesenchymal cells from WT and Ca v 3.2 −/− embryos. Ca v 3.2 −/− mesenchymal cells were able to undergo chondrogenic differentiation, but to a much less extent compared with WT mesenchymal cells (Fig.  2C) . Notably, treatment with NNC 55-0396 reduced chondrogenic differentiation in WT cells but did not affect the process further in Ca v 3.2 −/− cells. To confirm our observation of the positive association of Ca v 3.2 levels and chondrogenic differentiation, we used another T-type Ca 2+ channel blocker, mibefradil, and obtained results similar to those for NNC 55- −/− pups also significantly increased the mRNA levels of Sox9, Agc1, and Col2a1 (Fig. S4B) . Thus, in both ATDC5 and embryonic mesenchymal cells, Ca 2+ influx via Ca v 3.2 up-regulates the expression of chondrogenic markers and promotes chondrogenic differentiation.
Ca v 3.2 Enhances Chondrogenesis in a Calcineurin/NFAT-Dependent
Manner. We previously showed that Ca 2+ influx via Ca v 3.2 activates the calcineurin/NFAT signaling pathway, which then induces pathological cardiac hypertrophy (29) . Moreover, signaling by the calcineurin/NFAT pathway can induce chondrogenesis in vitro (38) . In addition, we have recently shown that Ca v 3.2 regulates the calcineurin/NFAT pathway through both Ca 2+ influx and calcineurin binding (39) . Thus, we hypothesized that Ca 2+ influx via Ca v 3.2 activates the calcineurin/NFAT signaling pathway to induce tracheal chondrogenesis. To test this hypothesis, we investigated the effects of the calcineurin inhibitor cyclosporin A (CsA) on the chondrogenic differentiation of ATDC5 cells with and without Ca v 3.2 overexpression. CsA attenuated the expected enhancement of Ca v 3.2-induced chondrogenic differentiation but had little effect on control cells (Fig. 3A) . Quantification of Alcian blue staining showed a 46% reduction in the CsA-treated, Ca v 3.2-overexpressing cells compared with control cells ( Fig. 3A ; P < 0.05). In addition, the expression of chondrogenic marker genes was significantly reduced in CsA-treated, Ca v 3.2-overexpressing ATDC5 cells but not their control counterparts (Fig.  3B) . The reduced percentages of Sox9, Agc1, and Col2a1 by CsA in Ca v 3.2-transfected ATDC5 cells are similar (62 ± 2.8%, 58 ± 3.3%, and 55 ± 3.5%, respectively), indicating the regulation of Sox9, Agc1, and Col2a1 is likely dependent on the same calcineurin/NFAT signaling pathway.
We also crossed Ca v 3.2 −/− mice with NFAT-luciferase (Luc) reporter transgenic mice (40) Sox9, one of the earliest markers of committed chondrogenic cells, is essential for early differentiation of chondrogenic cells (14) . Therefore, we examined the effect of the Ca v 3.2 null mutation on chondrogenic differentiation by assessing Sox9 expression. Sox9 protein was expressed on the ventrolateral sides of the tracheal tube at E11.5 and E13.5 in both WT and Ca v 3.2 −/− mice (Fig. 4A) . However, the Sox9 signal was significantly weaker in Ca v 3.2 −/− trachea than WT trachea at both E11.5 and E13.5 ( Fig. 4A) , even though the total number of mesenchymal cells at E11.5 was similar in WT and Ca v 3.2 −/− embryos (568 ± 33 and 566 ± 34, respectively). The reduced expression of Sox9 was observed throughout the embryonic Ca v 3.2 −/− tracheal tube (Fig. S5) . Furthermore, in vivo BrdU labeling of E13.5 embryos revealed no difference in the number of proliferating Sox9 + mesenchymal cells (Fig. S6B ). There is also no significant difference in the proliferating cell nuclear antigen-positive cells (Fig.  S6A) . A TUNEL assay also showed no difference in the apoptosis of embryonic WT and Ca v 3.2 −/− tracheas at E13.5 (Fig. S6C) . Thus, Ca v 3.2 may be an important modulator for Sox9 expression but not for mesenchyme cell proliferation or apoptosis during chondrogenesis in the trachea.
A certain level of Sox9 expression is essential for the condensation of chondroprogenitor cells into segments along developing trachea at E14.5 (14, 34) . Sox9-positive cells formed a clear banding pattern on the ventral side of developing trachea in WT but not Ca v 3.2 −/− mice (Fig. 4B) . The reduced Sox9-positive banding in Ca v 3.2 −/− mice may be due to a specific loss of Sox9 expression, impaired mesenchymal condensation during tracheal cartilage development, or both. Thus, we examined the expression pattern of another mesenchymal cell marker, paired-related homeobox gene-1 (Prx1) in embryonic tracheas (41, 42) . Prx1 is a homeobox-containing gene that is expressed in the mesenchymal cells differentiating into facial, limb, and vertebrate skeleton during embryogenesis (41) . In limb bud mesenchymal cells, the expression of Prx1 preceded that of Sox9 (42). Our results showed that Prx1-positive cells also formed a clear banding pattern on the ventral side of developing trachea in WT mice and a disrupted banding pattern in Ca v 3.2 −/− mice (Fig. 4B) . Interestingly, the staining intensity of Prx1 in each prechondrogenic condensate was similar in both WT and Ca v 3.2 −/− tracheas ( Fig. 4B and Fig.  S7 ). These results show that lack of Ca v 3.2 indeed affects the condensation of chondroprogenitor cells but not the expression of Prx1.
Sox9 regulates many chondrogenic marker genes, such as Agc1 and Col2a1 (43, 44) , and, indeed, the expression of both of these proteins was decreased in E16.5 Ca v 3.2 −/− trachea ( Fig. 4C) showed an essential promoter region located ∼750 bp upstream of the transcription start site (46) . We thus generated a construct that contains the equivalent mouse Sox9 sequence, from −735 to +53 bp, fused to a Luc reporter (−735-Luc) and generated serial 5′-deletions using this construct. It has been shown that increasing the extracellular Ca 2+ concentration to 10 mM can induce Ca 2+ influx via the Ca v 3.2 window currents at the resting membrane potential in nonexcitable cells (29, 39, 47) . Our positive control experiment demonstrated that the NFAT-response element (RE)-Luc reporter could be activated in a Ca v 3.2-dependent manner by increasing extracellular Ca 2+ concentration in ATDC5 cells (Fig. 5A) . Using this approach, we identified the Ca v 3.2-dependent fragment (from −499 to −312 bp) from which expression could be induced in calcium-treated Ca v 3.2-transfected ATDC5 cells (Fig. 5A) . The Ca v 3.2-dependent induction of −499-Luc reporter activity could be inhibited by treatment with NNC 55-0396, FK506, and CsA (Fig.  5B) . To confirm that Sox9 expression is regulated by NFAT, we expressed EGFP-NFATc4 in ATDC5 cells and found induced Sox9 expression (Fig. S8) . Coexpression of EGFP-NFATc4 also increased the reporter activity of −499-Luc (Fig. 5C) . Therefore, the Sox9 promoter region between −499 and −312 bp may be important for NFAT binding and Ca v 3.2 regulation. Using PROMO software (48), we identified a putative NFAT binding site (TTTCC, −489 to −485 bp) upstream of the Sox9 transcription start site and showed that mutations within this site (mut1 and mut2) abolished the NFAT dependence, as well as the Ca v 3.2 dependence, on the induction of −499-Luc reporter activity ( Fig. 5 C and D) . To confirm the interaction between NFAT and the putative NFAT binding site on the Sox9 promoter, we used an EMSA with a digoxigenin (DIG)-labeled oligonucleotide (−502 to −474 bp) as a probe. Lysates from EGFP-NFATc4 but not EGFP-transfected cells showed several shifted bands (Fig. 6A) . The shifted bands disappeared in the presence of excess unlabeled WT probe, but the upper band, which represents the NFAT-Sox9 DNA complex, remained, with the addition of an excess of unlabeled mutant probes unable to bind NFAT (mut1 or mut2). Therefore, the putative NFAT binding site is essential for the interaction between NFAT and the Sox9 promoter. An anti-GFP antibody could supershift the NFAT-Sox9 promoter complex (Fig. 6A) . Thus, NFAT could bind to the TTTCC sequence of the mouse Sox9 promoter.
To demonstrate that NFAT binds to the Sox9 promoter in vivo, we used a ChIP assay to examine enrichment of 227 bp containing the NFAT binding sequences in Sox9 promoter pulled down with EGFP-NFATc4 in ATDC5 cells. Compared with the EGFP control, the precipitated product with EGFP-NFATc4 showed a significantly enriched 227 bp of Sox9 promoter detected by PCR or real-time PCR (Fig. 6 B and C) . Combined with the fact that overexpressing NFAT increased Sox9 expression (Fig. S8) , as well as with the results of EMSA experiments (Fig. 6A) and Luc reporter assays (Fig. 5) , these results suggest that NFAT regulates Sox9 expression by binding to the TTTCC sequence of the mouse Sox9 promoter.
Discussion
Although many molecules are involved in chondrogenesis (49), little is known about the role of VGCCs in this process. T-type Ca 2+ channels are highly expressed in many developing tissues and are implicated in regulating cellular events leading to cell proliferation and differentiation (50) . Calcium influx through T-type Ca 2+ channels activates several cellular pathways, including calcineurin/NFAT (29, 39) , extracellular signal-regulated kinase (31, (51) (52) (53) , nitric oxide synthase 3 (54) , and Ca 2+ /calmodulindependent protein kinase II (55) . However, the detailed mechanisms linking these T-type Ca 2+ channel-activated signaling pathways to cell proliferation and differentiation are not completely clear. Interestingly, Ca v 3.1 is mostly linked to cell proliferation, whereas Ca v 3.2 is implicated in cell differentiation. Ca v 3.1 is involved in cell proliferation of smooth muscle cells (56) (57) (58) , tumor cells (59, 60) , and preadipocytes (61), but Ca v 3.2 is implicated in the differentiation of human skeletal muscle (62) , neuritogenesis of neuroblastoma cells (63, 64) , and neuroendocrine differentiation of prostate cancer cells (65) . In line with these studies, our data demonstrated that Ca v 3.2 is involved in tracheal chondrogenic differentiation but not proliferation or apoptosis of tracheal mesenchymal cells (Fig. S6) . Ca v 3.2 −/− mice did not show abnormal morphogenesis in cartilage other than trachea (Fig. S1C) The ATDC5 cell line is often used as a cellular model to assess chondrogenesis in vitro (36) . Ca v 3.2 T-type Ca 2+ channels can be detected by a specific Ca v 3.2 antibody in ATDC5 cells (18) . However, we could not detect the presence of Ca v 3.2 in ATDC5 cells using either RT-PCR (Fig. S3A) or the whole-cell patchclamp technique (Fig. S3B) . Under our recording condition, both T-type and L-type Ca 2+ channels can be activated and recorded if present. Even though the transcript of Ca v 1.2 can be detected in ATDC5 cells (Fig. S3A) , we cannot detect the calcium influx via L-type Ca 2+ channels (Fig. S3B) . These results suggest that in our culture condition, ATDC5 cells did not express detectable T-type or L-type Ca 2+ channels using an electrophysiological technique. (67, 68) , Orai 1 (69), acid-sensing ion channel (70) , and transient receptor potential (TRP) (71) channels, are identified in chondrocytes. The role of these channels in chondrocytes is not completely understood. TRPV4-mediated Ca 2+ influx is involved in transmitting the mechanotransduction signals to increased ECM production (72) . The TRPV4 channel is important for osmotically activated Ca 2+ signaling in articular chondrocytes, and lack of TRPV4 in mice leads to progressive increases in bone density and joint degradation (73) . However, it has not been reported that these channels are involved in tracheal chondrogenesis. These results support the idea that Ca v 3.2 plays a specific role in regulating the development of tracheal cartilage rings.
One may argue that the abnormal tracheal phenotype in the Ca v 3.2 −/− mice is because of a closure failure of the tracheal rings rather than a problem with cartilage formation. If the tracheal rings are formed by migration of chondrocytes from the bilateral sides to the ventrocentral part of the trachea, we would expect to observe a temporary gap in the cartilage ring during development in WT trachea. However, we never observed a broken Alcian blue staining pattern in the WT trachea. The earliest time point when Alcian blue staining could be observed was E14.5, with a clear cartilage banding pattern (Fig. 1A) . In addition, immunostaining of Sox9 and Prx1 showed a clear banding pattern on the ventrocentral part of the WT trachea at E14.5 (Fig. 4) . Immunostaining of Sox9 on the cross-section of the WT trachea at E13.5 also showed continuous staining on the ventrocentral part of the tracheal tube (Fig. 4 and Fig. S5 ). These data suggest that during normal tracheal cartilage development, the cartilaginous rings are formed by mesenchymal cells differentiated from the condensed mesenchymal cells surrounding the tracheal tube but not by chondrocytes migrating from the ventrolateral side of the tracheal tube. Thus, the abnormal tracheal phenotype in the Ca v 3.2 −/− mice most likely resulted from defective cartilage formation rather than closure of the tracheal rings resulting from migration or patterning defects.
The transcription factor Sox9 plays important roles in sex determination and chondrogenesis during development (9) (10) (11) . During chondrogenesis, Sox9 is required for mesenchymal cell condensation and the expression of cartilage-specific ECM genes, including Col2a1, Col11a2, and Agc1 (11, 14, 43, 44, 74) . Even though Sox9 is crucial in chondrogenesis, its regulation remains unclear, and only a few transcriptional factors were found to regulate Sox9 expression directly. For example, Sp1, the cyclic-AMP response element binding protein, NF-κB, and CCAAT binding factor can bind to the promoter region of Sox9 and promote its expression in chondrocytes (75) (76) (77) . We identified an NFAT binding motif (TTTCC) in the mouse Sox9 promoter that was required for Ca v 3.2-dependent Sox9 regulation on Luc reporter assay. In addition, NFAT directly bound to the identified sequence on gel shift, supershift, and ChIP assays. In agreement with our results, the calcineurin/NFAT signaling pathway induced chondrogenesis in vitro (38) and constitutively active NFAT induced the expression of Sox9 in C17 chondroprogenitor cells (78) . SOX9 haploinsufficiency results in a lethal skeletal malformation syndrome called campomelic dysplasia in humans (15) . Disruption of Sox9 also leads to perinatal lethality in heterozygous mice (11, 14) . These results show that a 50% reduction of Sox9 already leads to a lethal phenotype in humans and mice. In mice lacking sonic hedgehog, the level of Sox9 is almost absent at the time of chondrogenesis, resulting in the failure of tracheal cartilage formation (34) . The reduced percentage of Sox9 in Ca v 3.2 −/− trachea (Fig. 4) is around 30%; in Ca v 3.2 −/− mice, this reduction is enough to lead to malformation of the tracheal cartilage ring but not severe enough to cause a lethal phenotype.
In humans, CTMs can be observed in several disorders (79) [e.g., Pfeiffer syndrome (80), Goldenhar's syndrome (81), atelosteogenesis type 1 (82) ]. The molecular mechanism leading to CTMs is not understood and is believed to be multifactorial. CTMs have been described in mice lacking genes involved in embryonic development [e.g., sonic hedgehog (6), Wnt (83, 84) , bone morphogenetic protein (85, 86) , FGFs (87, 88) ]. Recently, mice with cartilage-specific deletion of Dicer 1 showed abnormal tracheal development because of a lack of ECM deposition (89) . Most of these mutant mice die embryonically or shortly after birth because of the severe and complicated embryonic defects. We are the first, to our knowledge, to show that VGCCs are involved in the development of tracheal cartilage. Mice lacking chloride channels, cystic fibrosis transmembrane conductance regulator (CFTR) (90), or transmembrane protein 16A (TMEM16A) (7) also show abnormal tracheal cartilaginous rings; however, the tracheal cartilage defects in CFTR −/− and TMEM16A −/− mice may be secondary to defects in the tracheal epithelium (7, 90) . Hence, our study provides novel insight into the roles of Ca v 3.2 T-type Ca 2+ channels in tracheal development. Moreover, CACNA1H, the human homolog of the mouse Ca v 3.2-encoding gene, may be a potential candidate gene involved in congenital tracheal stenosis in humans.
Materials and Methods
Animals. All research conformed to National Institutes of Health guidelines and those of the Institutional Animal Care and Utilization Committee, Academia Sinica. Ca v 3.2 −/− and NFAT-Luc mice were generated as described (28, 40 with insulin, transferrin, and sodium selenite supplement for 12 d as described (36) . ATDC5 cells transfected with Ca v 3.2 or control plasmid (pcDNA3) using a Neon Transfection System (Invitrogen) were selected with 600 μg/mL G418, and the medium was changed every other day for 2 wk. During induction of chondrogenesis, the G418 concentration was reduced to 60 μg/mL. For micromass chondrogenesis, the limb mesenchymal cells in 2:3 DMEM/Ham F-12 medium containing 10% (vol/vol) FBS were cultured at a density of 1 × 10 7 cells/mL as described (38) . ATDC5 and micromass cultures were changed every other day until harvesting and were supplemented with DMSO (vehicle), CaCl 2 (10 mM), FK506 (2.5 μM, a calcineurin inhibitor), CsA (2.5 μM), NNC 55-0396 (5 μM), or mibefradil (10 μM). Alcian blue (Sigma) staining, RNA isolation, quantitative RT-PCR, and the Luc reporter assay are described in SI Materials and Methods.
In Situ Hybridization. In situ hybridization of paraffin sections was done as previously described (91), using a DIG-labeled RNA system (Roche). A Ca v 3.2-specific probe was generated by RT-PCR and subcloned into pBluescript II Kpn 1/Sac I plasmid. Anti-DIG-alkaline phosphatase antibody was used to detect the RNA probe, and color was developed by use of nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl-phosphate.
Immunohistochemistry. Paraffin sections (5 μm) were deparaffinized by boiling in 0.01 M sodium citrate, blocked in 3% (vol/vol) goat serum, and incubated with primary antibody overnight at 4°C. Sections were then rinsed with PBS and incubated with biotinylated secondary antibody (1:200 dilution; Vector Labs) for 60 min. The antigen/antibody complexes were detected by sequential use of kits for detection of avidin/biotin complex (Vector Labs) and diaminobenzidine (Vector Labs). The following primary antibodies were used: anti-Sox9 and rabbit polyclonal anti-Luc (Santa Cruz Biotechnology), anti-Agc1 (Millipore), anti-Col2a1 (Abcam), and anti-Luc (Santa Cruz Biotechnology). The immunostaining intensities of Sox9, Agc1, and Col2a1 were analyzed using a HistoQuest system (TissueGnostics). Sox9-positive cells around the tracheal tube at E11.5 were counted as mesenchymal cells.
EMSA. Synthetic oligonucleotides containing the NFAT binding site of Sox9 and the complementary oligonucleotide were 3′ end-labeled with the use of DIG-11-ddUTP (Roche) and terminal transferase (New England Biolabs)
following the manufacturers' instructions and then annealed. The probes were incubated for 20 min at room temperature with 10 μg of HEK cell lysates containing the EGFP or EGFP-NFATc4 protein; 1 μg of poly(deoxyinosinicdeoxycytidylic) acid; and 0.1 μg of poly L-lysine in buffer containing 20 mM Hepes-KOH (pH 7.6), 1 mM EDTA, 10 mM (NH4) 2 SO 4 , 1 mM DTT, 0.2% Tween 20, and 30 mM KCl. For the competition assay, unlabeled WT or mutantannealed oligonucleotide was added at 125-fold excess for 10 min at room temperature before the probe was added. For analysis of supershift induction, 8 ng of GFP antibody (monoclonal anti-GFP; Sloan-Kettering Cancer Center) was added for 20 min at room temperature before the probe was added. The reaction products were analyzed on 6% nondenaturing polyacrylamide gel.
ChIP Assay. A total of 6 × 10 6 ATDC5 cells were used for each immunoprecipitation as described earlier (92) . Rabbit anti-GFP antibody (ChIP grade; Abcam) or control rabbit IgG (Sigma) was used for immunoprecipitation.
DNA was purified and amplified by real-time quantitative PCR (qPCR). Data were expressed as the percentage of input DNA associated with immunoprecipitated GFP relative to the input chromatin. Oligonucleotides sequences used for RT-PCR, in situ hybridization, EMSA, ChIP and qPCR assays are listed in Table S1 .
Statistical Analysis. Data are presented as mean ± SEM. Statistical analysis involved the Student t test or one-way ANOVA for more than two sample groups and Tukey's post hoc analysis. P < 0.05 was considered statistically significant.
